De Novo device
SoClean 3+ Bacterial Reduction Device
Soclean, Inc. · Respiratory Accessory Microbial Reduction Device. (QXQ, Class II) · First FDA decision Aug 12, 2024, newest Aug 12, 2024Sleep apnea
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
101
Naming "3+ Bacterial"
MAUDE reports
0
Brand "3+ Bacterial", since 2015
PubMed studies
368
Mentioning "3+ Bacterial"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing SoClean 3+ Bacterial Reduction Device
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 1 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "3+ Bacterial", any status and sponsor, newest update first.
Saglik Bilimleri UniversitesiAcademic, hospital or other
NCT07811921 · 70 participants (planned) · Start Oct 15, 2026 · Primary completion Apr 15, 2027
Device: Mechanical Debridement with Titanium Curettes; Mechanical Debridement with Plastic Curettes and 2 more · For: Peri-implantitis
Sites: Ankara, Turkey (Türkiye)
Assiut UniversityAcademic, hospital or other
NCT07859358 · 24 participants · Start Jan 20, 2026 · Primary completion Apr 20, 2026
Device: Custom Acrylic Probing Sten · For: Stage III Periodontitis
Sites: Asyut, Egypt · 2 sites in all
- A Study of Different Skin Care Approaches to Prevent Skin Reactions in People With Breast Cancer Receiving Radiation Therapy After MastectomyPivotal-lookingRecruiting
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT07918989 · 138 participants (planned) · Start Oct 30, 2026 · Primary completion Oct 30, 2028
Device: Mepitel Film · For: Breast Cancer; Breast Cancer Female
Sites: Basking Ridge, New Jersey; Middletown, New Jersey; Montvale, New Jersey · 7 sites in all
98 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "3+ Bacterial", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QXQ
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "3+ Bacterial"[tiab]. The summary above synthesizes these.
- Addressing antibiotic resistance.
Gupta K · Am J Med · 2002Review
- Bacterial secreted effectors and caspase-3 interactions.
Wall DM, McCormick BA · Cell Microbiol · 2014Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Addressing antibiotic resistance.
Gupta K · Dis Mon · 2003Review
- Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study.
Horwitz ME, Stiff PJ, Cutler C, et al. · Blood · 2021Clinical Trial, Phase III, Comparative Study
- Blending Three Probiotics Alleviates Loperamide-Induced Constipation in Sprague-Dawley (SD)-Rats.
Jang YJ, Moon JS, Kim JE, et al. · Food Sci Anim Resour · 2024
- A microfluidic biosensor for rapid simultaneous detection of waterborne pathogens.
Muhsin SA, Al-Amidie M, Shen Z, et al. · Biosens Bioelectron · 2022
- The gut microbiome and the brain.
Galland L · J Med Food · 2014Review
- ROS generating BODIPY loaded nanoparticles for photodynamic eradication of biofilms.
Kromer C, Schwibbert K, Radunz S, et al. · Front Microbiol · 2023
- Application of built-in adjuvants for epitope-based vaccines.
Lei Y, Zhao F, Shao J, et al. · PeerJ · 2019
- Construction of high-quality genomes and gene catalogue for culturable microbes of sugarcane (Saccharum spp.).
Wu L, Lin H, Zhang L, et al. · Sci Data · 2024Dataset, Research Support, Non-U.S. Gov't
- Impact of P-selectin-PSGL-1 Axis on Platelet-Endothelium-Leukocyte Interactions in Fatal COVID-19.
Granai M, Warm V, Vogelsberg A, et al. · Lab Invest · 2023Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code QXQ.
- Paptizer 360LiViliti Health Products Corporation · 510(k) 2026
- SoClean 3+Soclean, Inc. · 510(k) 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.